Tackling Drug-Resistant Tuberculosis
Current TB treatments are complex and often poorly tolerated, exacerbated by high rates of drug resistance. The WHO estimates that in 2022, treatment success rate for people diagnosed with MDR/rifampicin-resistant TB was only 63%. Even if cured, many patients have an impaired quality of life, mainly due to post-TB lung disease. The EU-funded DRTB-HDT project aims to prevent these poor treatment outcomes. Our innovative approach involves two adjunctive host-directed therapies that will be tested in a randomised, controlled, three-arm, multicentre trial. The project is a crucial step in addressing the global challenge of drug-resistant TB by developing new treatments that increase the likelihood of cure and reduce the risk of lifelong disability.
Read more about DRTB-HDT